Bronchogen is a short-chain bioregulatory peptide studied in preclinical models for its role in bronchial epithelial tissue gene expression and cellular homeostasis. PX1 Research supplies high-purity, laboratory-grade Bronchogen manufactured to rigorous analytical standards, enabling precise thermodynamic evaluation including enthalpy change ($ΔH$) assays, differential scanning calorimetry, and molecular binding investigations.
Bronchogen is a short-chain bioregulatory peptide studied in preclinical models for its role in bronchial epithelial tissue gene expression and cellular homeostasis. PX1 Research supplies high-purity, laboratory-grade Bronchogen manufactured to rigorous analytical standards, enabling precise thermodynamic evaluation including enthalpy change ($ΔH$) assays, differential scanning calorimetry, and molecular binding investigations.
Evaluating Bronchogen enthalpy change (ΔH) requires a professional manufacturer capable of delivering ultra-pure, batch-consistent peptide sequences. Enthalpy change measures the heat absorbed or released during peptide solvation, receptor binding, or conformational transition. PX1 Research manufactures research-grade Bronchogen under stringent ISO 17025 analytical oversight to guarantee structural integrity, precise molar mass, and consistent thermodynamic behavior in laboratory assays.
In physical chemistry and molecular biology assays, the enthalpy change (ΔH) associated with short synthetic peptides like Bronchogen provides critical data regarding hydrogen bonding, hydrophobic interactions, and conformational stability. When researchers evaluate thermodynamic parameters via Isothermal Titration Calorimetry (ITC) or Differential Scanning Calorimetry (DSC), even trace impurities, TFA salts, or residual moisture can skew experimental heat capacity measurements. As an established US-based peptide supplier, PX1 Research utilizes precise solid-phase peptide synthesis (SPPS) followed by rigorous lyophilization protocols to ensure optimal physical properties for accurate thermodynamic profiling.
Bronchogen is a synthetic tetrapeptide consisting of the amino acid sequence L-alanyl-L-alpha-aspartyl-L-alpha-glutamyl-L-leucine (Ala-Asp-Glu-Leu). Developed within the framework of short bioregulatory peptide research, its low molecular weight allows for distinct solubility dynamics and interaction profiles within target cellular matrixes. Investigating the molecular properties of the Bronchogen peptide requires an understanding of how its charged side chains (aspartic acid and glutamic acid) contribute to ionic interactions and local hydration shells.
Preclinical literature indicates that short peptide sequences interact directly with chromatin structure and specific DNA promoter regions. Because these interactions are governed by non-covalent bonding forces, measuring the enthalpy change (ΔH) during peptide-nucleic acid or peptide-protein association offers valuable insight into the energetic drivers of bioregulatory recognition mechanisms. PX1 Research provides fully characterized sequences to support advanced structural biology and biophysical research.
The total enthalpy change (ΔH_total) of a peptide solution during reconstitution involves several thermodynamic contributions: the lattice energy breakdown of the lyophilized solid, the enthalpy of hydration for ionic and polar residue side chains, and structural reorganization of the solvent molecules. For a short tetrapeptide like Bronchogen, negative solvation enthalpy values typically reflect favorable electrostatic interactions between water molecules and the carboxylate groups of Asp and Glu.
When designing calorimetry experiments, investigators must account for buffer composition, pH, and ionic strength, as these variables markedly alter the experimental enthalpy change. High-purity peptides synthesized without counter-ion variation allow laboratories to isolate the intrinsic thermodynamic variables of the peptide. Browse our complete catalog of all research compounds to select standardized reagents for physical chemistry and structural biology studies.
In vitro data and rodent models suggest that Bronchogen plays a potential role in modulating gene expression within bronchial epithelial cells. Preclinical investigations have documented changes in expression markers associated with cellular differentiation, mucociliary clearance mechanisms, and antioxidant response pathways following peptide exposure in primary culture systems.
Furthermore, animal models evaluating lung tissue homeostasis have explored whether short peptides alter inflammatory signaling cascades or fibroblast proliferation following oxidative challenge. These preclinical studies emphasize that maintaining structural purity during synthesis is essential for reproducing scientific findings across independent laboratory trials.
Bronchogen belongs to a broader class of short synthetic peptide bioregulators developed to investigate tissue-specific regulation and epigenetic mechanisms. Comparing its structural and thermodynamic characteristics against related research compounds highlights specific structure-activity relationships inherent to short peptide sequences.
For example, researchers frequently examine Bronchogen alongside Epitalon, a tetrapeptide evaluated for its interactions with telomerase activity and chromatin structure. Similarly, studies examining immune and mucosal barrier function often compare Bronchogen with Vilon research profiles or review Thymogen preclinical overview data to assess differential tissue selectivity. While Epitalon and Vilon exhibit distinct charge distributions and target profiles, all three compounds demonstrate how minor sequence modifications alter the enthalpy change (ΔH) of folding and binding in target assays.
Producing stable, highly pure research peptides demands strict control over every phase of synthesis. PX1 Research utilizes state-of-the-art Solid-Phase Peptide Synthesis (SPPS) platforms in GMP-compliant facilities located in California and Arizona. Controlling coupling efficiency and cleavage conditions prevents side reactions, such as aspartimide formation or incomplete deprotection, which can alter the peptide's thermodynamic properties.
Following synthesis, raw peptides undergo deep purification via preparative Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC). This process isolates the target sequence from truncated fragments or residual reactants. The purified solution is then lyophilized under controlled temperature and vacuum parameters to yield a uniform, crystalline powder optimized for reconstitutive solubility and long-term shelf stability.
To ensure that laboratory results reflect true compound activity rather than artifactual interference, PX1 Research subjects every lot of Bronchogen to exhaustive third-party analytical testing at accredited ISO 17025 laboratories. Certificates of Analysis (COAs) accompany every shipment, confirming identity, purity, and safety metrics.
Purity is verified via RP-HPLC, confirming a minimum purity threshold of ≥98%. Electrospray Ionization Mass Spectrometry (ESI-MS) confirms the exact molecular mass, matching the theoretical weight of the Bronchogen sequence. Additionally, because bacterial endotoxins can confound cell culture and calorimetric assays by altering thermal dynamics or triggering non-specific immune responses, PX1 performs quantitative Chromogenic LAL endotoxin testing to guarantee ultra-low endotoxin levels (<0.01 EU/mg). For detailed methodology on our quality assurance pipelines, visit our analytical peptide purity testing guide.
Proper handling protocols are critical to maintaining the structural integrity and thermodynamic performance of lyophilized Bronchogen. Upon receipt, sealed vials should be stored in a dry, dark environment at -20°C or -80°C for long-term preservation. Exposure to ambient moisture or repeated freeze-thaw cycles can induce peptide degradation, aggregation, or hydrolysis.
For reconstitution in laboratory applications, researchers should allow the vial to equilibrate to room temperature before opening to minimize condensation. Reconstitute the peptide using sterile target buffers (such as PBS or ultra-pure laboratory-grade water) suited to your specific experimental assay. After reconstitution, aliquot the solution into single-use microcentrifuge tubes and store at -80°C to prevent repeated thermal stress. Institutional facilities requiring larger volume orders for ongoing screening programs can access our bulk lab ordering portal.
What is Bronchogen enthalpy change and why is it measured?
Bronchogen enthalpy change (ΔH) refers to the heat absorbed or released during physical or chemical processes involving the peptide, such as dissolution, conformational shifts, or receptor binding. Measuring ΔH using Isothermal Titration Calorimetry (ITC) provides essential data regarding the thermodynamic forces driving peptide interactions in preclinical research.
What purity level does PX1 Research guarantee for Bronchogen?
PX1 Research guarantees that all Bronchogen lots meet or exceed ≥98% purity as determined by Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) and mass spectrometry.
How does PX1 Research verify batch consistency and thermodynamic quality?
Every lot manufactured by PX1 Research undergoes third-party verification at an ISO 17025 accredited laboratory. Testing includes RP-HPLC for purity, ESI-MS for molecular identity, and LAL assays for endotoxin quantification. Full COAs are published per lot.
What are the recommended storage conditions for research-grade Bronchogen?
Lyophilized Bronchogen should be stored at -20°C or -80°C in a desiccated environment. Reconstituted solutions should be aliquoted and maintained at -80°C to avoid degradation from freeze-thaw cycles.
Can Bronchogen be used for human administration or clinical therapy?
No. Bronchogen supplied by PX1 Research is strictly for in vitro, preclinical, and laboratory research use only. It is not approved for human or animal therapeutic, diagnostic, or clinical applications.
What buffer systems are recommended for calorimetry assays involving Bronchogen?
Common buffer systems include standard Phosphate-Buffered Saline (PBS) or Tris-HCl, depending on the pH requirements of the enthalpy assay. Researchers should select buffers with minimal ionization enthalpy to avoid masking the intrinsic binding heat of the peptide.
Where is PX1 Research Bronchogen manufactured and shipped from?
All PX1 Research compounds are manufactured in US-based GMP-compliant facilities and shipped directly from fulfillment hubs in California and Arizona with same-day dispatch for orders placed Monday through Friday.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.